An estimated 40 percent of senior dogs 12 or older will develop some level of canine cognitive dysfunction, also known as dog dementia. A pilot clinical trial conducted for dogs with CCD looked at the drug Ropesalazine, which is a candidate for treating human Alzheimer’s patients.
According to the drug’s manufacturer, South Korea-based GNT Pharma, Ropesalazine showed efficacy in canine dementia patients, returning to a normal cognitive function and daily activity after eight weeks of treatment.
Thumbnail: Photography ©CatLane | Getty Images.
Jackie Brown is a freelance writer from Southern California who specializes in the pet industry. Reach her at jackiebrownwriter.wordpress.com.
Editor’s note: This article appeared in Dogster magazine. Have you seen the new Dogster print magazine in stores? Or in the waiting room of your vet’s office? Subscribe now to get Dogster magazine delivered straight to you!